A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension.
CONCLUSIONS: The triple combination therapy with AZL/AML/HCTZ was well tolerated and effective for 52 weeks in Japanese patients with essential hypertension.
PMID: 29235365 [PubMed - as supplied by publisher]
Source: Blood Pressure - Category: Hematology Tags: Blood Press Source Type: research
More News: Calcium | Hematology | Hydrochlorothiazide | Hypertension | Japan Health | Norvasc | Study